uniQure

About uniQure

uniQure is a global leader in gene therapy with a mission to reimagine the future of medicine by delivering innovative cures that transform lives. With over 20 years of innovation and industry firsts, the company focuses on genomic medicine to revolutionize healthcare.

Products & Services

AMT-130 for Huntington's Disease:A gene therapy program targeting Huntington's Disease, currently aligned with FDA for an Accelerated Approval pathway.

AMT-260 for Refractory Mesial Temporal Lobe Epilepsy (MTLE):A gene therapy in Phase I/IIa trials showing significant seizure reduction in initial participants.

Hemophilia B Program:A gene therapy initiative focused on treating Hemophilia B.

Fabry Disease Program:A gene therapy program aimed at addressing Fabry Disease.

ALS (SOD1) Program:A gene therapy targeting Amyotrophic Lateral Sclerosis (ALS) with SOD1 mutation.

Specialties

Gene Therapy Genomic Medicine AAV Platform Technology Neurological Disorders Rare Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 345000000 MR: - FA: approximately $345 million FAN: 345000000	D: 2025-09-29 FD: 2025-09-29	5 investors
2	RT: Public Offering T: - FT: Public Offering	A: 300000000 MR: - FA: approximately $300 million FAN: 300000000	D: 2025-09-25 FD: 2025-09-25	5 investors
3	RT: Debt T: - FT: Debt	A: 175000000 MR: - FA: $175 million FAN: 175000000	D: 2025-09-24 FD: 2025-09-24	1 investors
4	RT: Public Offering T: - FT: Public Offering	A: 200000000 MR: - FA: 200 million FAN: 200000000	D: 2025-09-24 FD: 2025-09-24	4 investors
5	RT: Public Offering T: - FT: Public Offering	A: 75000000 MR: - FA: approximately $75 million FAN: 75000000	D: 2025-01-08 FD: 2025-01-08	5 investors

Public Offering Latest

2025-09-29

$345.0M

5 investors (Pro only)

Public Offering 2025-09-25

$300.0M

Debt 2025-09-24

$175.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Martin Kangwa

Senior Scientist, Process Development

N

Nathalie Pech-Zwahlen

VP Strategic Planning Lead

V

Vanessa Zancanella

Sr. Scientist

M

Matt Kapusta

Chief Executive Officer

W

Walid Abi-Saab

Chief Medical Officer

A

Amin Abujoub

Chief Technical Operations Officer

View 14 more team members with Pro

Unlock Full Team Directory

Recent News

uniQure Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised